Tammy Hill
Adult Health · Russell Springs, KYNPI 1831172170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $577 and has fallen 67.6% since, to $187 in 2025.
Across 96 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$251
- AstraZeneca$220
- Novartis$210
- Boehringer Ingelheim$153
- AbbVie$134
- GSK$129
- plus $629 from 13 others
What the payments were for
- Food & beverage$1,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $251 |
| AstraZeneca | 11 | $220 |
| Novartis | 12 | $210 |
| Boehringer Ingelheim | 10 | $153 |
| AbbVie | 6 | $134 |
| GSK | 7 | $129 |
| Optinose US, Inc. | 2 | $121 |
| Lilly USA, LLC | 8 | $118 |
| Abbott | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Bayer | 3 | $47 |
| Amgen(2 entities) | 3 | $47 |
| Pfizer | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Merck | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$110
How this compares
$1,725 in reported general payments places this provider in the 75th percentile of 170 adult health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $96,467 |
| JanuviaSitagliptin Phosphate | 80 | $60,777 |
| FarxigaDapagliflozin Propanediol | 90 | $57,536 |
| EliquisApixaban | 62 | $38,307 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,824 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $29,666 |
| MounjaroTirzepatide | 20 | $28,639 |
| JardianceEmpagliflozin | 45 | $26,918 |
| EntrestoSacubitril/Valsartan | 30 | $26,389 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $24,875 |
| TrulicityDulaglutide | 23 | $24,010 |
| XareltoRivaroxaban | 25 | $23,419 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $20,880 |
| LinzessLinaclotide | 29 | $20,426 |
| RybelsusSemaglutide | 14 | $15,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $251 | $111,84293 claims |
| MerckJanuvia, Steglatro | $17 | $69,581105 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $220 | $67,778115 claims |
| Lilly USA, LLCMounjaro, Trulicity | $118 | $52,64943 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $129 | $49,38872 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $153 | $39,81172 claims |
| PfizerEliquis | $39 | $38,30762 claims |
| NovartisEntresto | $210 | $26,38930 claims |
| AbbVieLinzess, Synthroid | $134 | $23,22975 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $6,19912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 170 adult health providers in Kentucky.
Other adult health in Russell Springs
- Carrie Clifford-BennettGeorgetown$730K
- Stephanie FlaspoehlerLouisville$174K
- Kimberly VesselsBrandenburg$58K
- Heidi GalloLouisville$15K
- Amy BakerPaducah$14K
- Joyce JohnsonElizabethtown$12K
- Karen EastridgeLouisville$10K
- Seon Hui BalistrereHopkinsville$8K
- Barbara CarpenterLouisville$8K
- Jennifer ThomasPaducah$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.